## Hulya Apaydin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8525985/publications.pdf

Version: 2024-02-01

471509 243625 2,207 56 17 44 citations h-index g-index papers 59 59 59 2777 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Collection and Analysis of a Parkinson Speech Dataset With Multiple Types of Sound Recordings. IEEE Journal of Biomedical and Health Informatics, 2013, 17, 828-834.	6.3	459
2	Parkinson Disease Neuropathology. Archives of Neurology, 2002, 59, 102.	4.5	366
3	A comparative analysis of speech signal processing algorithms for Parkinson's disease classification and the use of the tunable Q-factor wavelet transform. Applied Soft Computing Journal, 2019, 74, 255-263.	7.2	325
4	The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease. Journal of Neuroimmunology, 2015, 283, 50-57.	2.3	197
5	Vascular Dementia in a Population-Based Autopsy Study. Archives of Neurology, 2003, 60, 569.	4.5	194
6	Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder. Clinical Neurology and Neurosurgery, 2005, 107, 306-309.	1.4	83
7	Broad bean (Vicia faba)?A natural source ofL-dopa?Prolongs ?on? periods in patients with Parkinson's disease who have ?on-off? fluctuations. Movement Disorders, 2000, 15, 164-166.	3.9	82
8	An updated comprehensive systematic review of Cladophialophora bantiana and analysis of epidemiology, clinical characteristics, and outcome of cerebral cases. Medical Mycology, 2016, 55, myw124.	0.7	45
9	FBXO7 mutations in Parkinson's disease and multiple system atrophy. Neurobiology of Aging, 2016, 40, 192.e1-192.e5.	3.1	43
10	Features associated with the development of hallucinations in Parkinson's disease. Acta Neurologica Scandinavica, 2006, 114, 239-243.	2.1	42
11	GC and VDR SNPs and Vitamin D Levels in Parkinson's Disease: The Relevance to Clinical Features. NeuroMolecular Medicine, 2017, 19, 24-40.	3.4	38
12	Two siblings with homocystinuria presenting with dystonia and parkinsonism. Movement Disorders, 2004, 19, 962-964.	3.9	26
13	Delayed-onset dystonia associated with 3-oxothiolase deficiency. Movement Disorders, 2001, 16, 372-375.	3.9	22
14	A hospital-based study: Risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy. Clinical Neurology and Neurosurgery, 2006, 108, 726-732.	1.4	21
15	Apraxia in Parkinson's disease and multiple system atrophy. European Journal of Neurology, 2010, 17, 413-418.	3.3	21
16	Estimation of Parkinson's disease severity using speech features and extreme gradient boosting. Medical and Biological Engineering and Computing, 2020, 58, 2757-2773.	2.8	21
17	A consanguineous Turkish family with early-onset Parkinson's disease and an exon 4 parkin deletion. Movement Disorders, 2004, 19, 812-816.	3.9	20
18	Rapid Alleviation of Parkinson's Disease Symptoms via Electrostimulation of Intrinsic Auricular Muscle Zones. Frontiers in Human Neuroscience, 2017, 11, 338.	2.0	20

#	Article	IF	CITATIONS
19	Assessment of movement time in patients with essential tremor. Journal of Neurology, 2005, 252, 964-967.	3.6	17
20	Posthemiplegic focal limb dystonia: A report of two cases. Clinical Neurology and Neurosurgery, 1998, 100, 46-50.	1.4	16
21	Treatment of Homocystinuria-Related Dystonia with Deep Brain Stimulation: A Case Report. Stereotactic and Functional Neurosurgery, 2011, 89, 210-213.	1.5	15
22	A case of central nervous system infection due to Cladophialophora bantiana. Revista Iberoamericana De Micologia, 2016, 33, 237-241.	0.9	13
23	Auditory startle reflex and startle reflex to somatosensory inputs in generalized dystonia. Clinical Neurophysiology, 2015, 126, 1740-1745.	1.5	12
24	Altered Transcriptional Profile of Mitochondrial DNA-Encoded OXPHOS Subunits, Mitochondria Quality Control Genes, and Intracellular ATP Levels in Blood Samples of Patients with Parkinson's Disease. Journal of Alzheimer's Disease, 2020, 74, 287-307.	2.6	12
25	High-dose piracetam is effective on cerebellar ataxia in patient with cerebellar cortical atrophy. Movement Disorders, 2003, 18, 457-459.	3.9	11
26	Psychogenic movement disorders in two children. Movement Disorders, 2003, 18, 1395-1397.	3.9	10
27	The Complex Genetic Landscape of Hereditary Ataxias in Turkey and Implications in Clinical Practice. Movement Disorders, 2021, 36, 1676-1688.	3.9	9
28	Cyanide-Induced Parkinsonism and F-18 FDG PET/CT Findings. Clinical Nuclear Medicine, 2006, 31, 363-364.	1.3	8
29	Successful treatment of Juvenile parkinsonism with bilateral subthalamic deep brain stimulation in a 14-year-old patient with parkin gene mutation. Parkinsonism and Related Disorders, 2016, 24, 137-138.	2.2	8
30	Cerebrotendinous Xanthomatosis: The Effectiveness of High-Dose Piracetam for the Treatment of Cerebellar and Sensorial Ataxia. Cerebellum, 2014, 13, 787-790.	2.5	7
31	Capgras Syndrome During the Course of Parkinson Disease Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2014, 26, E46-E46.	1.8	6
32	Sleep parameters associated with long-term outcome following subthalamic deep brain stimulation in Parkinson's disease. Revue Neurologique, 2020, 176, 277-284.	1.5	5
33	Genetic variants of vitamin D metabolism-related <i>DHCR7/NADSYN1</i> locus and <i>CYP2R1</i> gene are associated with clinical features of Parkinson's disease. International Journal of Neuroscience, 2022, 132, 439-449.	1.6	5
34	Hypertrophy of intima media of the carotid artery due to L-dopa therapy in Parkinson's disease. Advances in Therapy, 2008, 25, 201-207.	2.9	4
35	Myoclonus in the elderly: A retrospective analysis of clinical and electrophysiological characteristics of patients referred to an electrophysiology laboratory. Parkinsonism and Related Disorders, 2018, 49, 22-27.	2.2	4
36	Neuropathologic Changes in Parkinson Disease With Late Onset of Dementiaâ€"Reply. Archives of Neurology, 2003, 60, 453.	4.5	4

3

#	Article	IF	CITATIONS
37	Electrophysiological Investigations in Orthostatic Myoclonus: Preliminary Findings. Canadian Journal of Neurological Sciences, 2018, 45, 100-103.	0.5	3
38	The effect of kinesiophobia on physical activity, balance, and fear of falling in patients with Parkinson's disease. Physiotherapy Theory and Practice, 2023, 39, 865-872.	1.3	3
39	First imported coccidioidomycosis in Turkey: A potential health risk for laboratory workers outside endemic areas. Medical Mycology Case Reports, 2014, 3, 20-25.	1.3	2
40	P3-097: Serum interleukin 1 alpha and alpha 2 macroglobulin levels in patients with early- or late-onset Alzheimer's disease or mild cognitive impairment., 2015, 11, P657-P657.		2
41	A stimulusâ€sensitive tic disorder characterized by echophenomena and coprolalia. Movement Disorders, 2012, 27, 159-160.	3.9	1
42	Low Levels of LRRK2 Gene Expression are Associated with LRRK2 SNPs and Contribute to Parkinson's Disease Progression. NeuroMolecular Medicine, 2021, 23, 292-304.	3.4	1
43	Walking training augments the effects of expiratory muscle training in Parkinson's disease. Acta Neurologica Scandinavica, 2022, 145, 79-86.	2.1	1
44	Ataxia in a Movement Disorders Outpatient Clinic: a Single-Center Experience in Turkey. Cerebellum, 2022, , 1.	2.5	1
45	Hand Pronation–Supination Movement as a Proxy for Remotely Monitoring Gait and Posture Stability in Parkinson's Disease. Sensors, 2022, 22, 1827.	3.8	1
46	P2-184: MILD COGNITIVE IMPAIRMENT IN A PATIENT WITH EXTREME WIDENING OF VIRCHOW-ROBIN SPACES. , 2014, 10, P537-P538.		0
47	P3-082: Compromised regulation of serum cytokine levels and BDNF due to low levels of vitamin d in patients with early- or late-onset Alzheimer's disease or parkinson's disease., 2015, 11, P649-P650.		O
48	The Effect of Piracetam on Friedreich Ataxia. Clinical Neuropharmacology, 2016, 39, 159-160.	0.7	0
49	[P3–119]: LEUCINE RICH REPEAT KINASE 2 (LRRK2) SINGLE NUCLEOTIDE POLYMORPHISMS AND MRNA EXPRESSION LEVELS IN A TURKISH COHORT OF PATIENTS WITH PARKINSON'S DISEASE. Alzheimer's and Dementia, 2017, 13, P980.	0.8	O
50	P2â€⊋43: THE BLOOD PROFILE OF MTDNA ENCODED GENES EXPRESSION IN PARKINSON'S DISEASE PATIENTS AND HEALTHY INDIVIDUALS. Alzheimer's and Dementia, 2018, 14, P766.	0.8	0
51	P3â€109: ASSOCIATION BETWEEN NADSYN1/DHCR7 AND CYP2R1 GENOTYPES AND PARKINSON'S DISEASE AND ITS CLINICAL FEATURES. Alzheimer's and Dementia, 2018, 14, P1109.	0.8	0
52	Clinical and radiological findings of a rare case: reversible Parkinsonism in cerebral venous sinus thrombosis. Acta Neurologica Belgica, 2020, 120, 491-493.	1.1	0
53	Relationship Between Sleep-related Violence and NREM Parasomnia: A Case Report. Journal of Turkish Sleep Medicine, 2018, 5, 46-49.	0.5	O
54	Evaluation of Pre and Postoperative Polysomnographic Data in Patients with Idiopathic Parkinson's Disease Undergoing Deep Brain Stimulation Intended Bilateral Subthalamic Nucleus. Journal of Turkish Sleep Medicine, 2019, 6, 53-58.	0.5	O

#	Article	IF	CITATIONS
55	Comparison of pulmonary functions and quality of life in patients with parkinson's disease and multiple system atrophy. , 2020, , .		o
56	Comparison of two different methods for assessing inspiratory muscle strength in patients with multiple system atrophy: a pilot study. , 2020, , .		0